



Supplementary figure

Study designs of 4 SJIA studies with canakinumab.

Figure shows study designs of the 4 SJIA studies with canakinumab. Study 1 was a phase 3, randomised, double-blind, placebo-controlled study conducted in SJIA patients who received either canakinumab at 4 mg/kg or placebo. Study 2 was a phase 3 study, which included two parts: Part I, an open-label, steroid-tapering study and Part II, a double-blind, placebo-controlled study that assessed flare prevention. Study 3 was a phase 3, open-label extension study. Study 4 was a phase 2, open-label, dose-ranging study with two different stages (Stage I and Stage II). SJIA: systemic juvenile idiopathic arthritis.